- Home
- Publications
- Publication Search
- Publication Details
Title
PRSS contributes to cetuximab resistance in colorectal cancer
Authors
Keywords
-
Journal
Science Advances
Volume 6, Issue 1, Pages eaax5576
Publisher
American Association for the Advancement of Science (AAAS)
Online
2020-01-02
DOI
10.1126/sciadv.aax5576
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Optimizing sequential treatment with anti-EGFR and VEGF mAb in metastatic colorectal cancer: current results and controversies
- (2019) Datian Chen et al. Cancer Management and Research
- Serum Serine Peptidase Inhibitor Kazal-Type 1, Trypsinogens 1 to 3, and Complex of Trypsin 2 and α1-Antitrypsin in the Diagnosis of Severe Acute Pancreatitis
- (2019) Mia Rainio et al. PANCREAS
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Comparative Effectiveness and Safety of Monoclonal Antibodies (Bevacizumab, Cetuximab, and Panitumumab) in Combination with Chemotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
- (2018) Wânia Cristina da Silva et al. BIODRUGS
- Predictive role of UCA1-containing exosomes in cetuximab-resistant colorectal cancer
- (2018) Ying-nan Yang et al. Cancer Cell International
- Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study
- (2017) S. Stintzing et al. EUROPEAN JOURNAL OF CANCER
- Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
- (2016) Beth O. Van Emburgh et al. Nature Communications
- Neuroprotective Effect of Ulinastatin on Spinal Cord Ischemia-Reperfusion Injury in Rabbits
- (2015) Bingbing Liu et al. Oxidative Medicine and Cellular Longevity
- SPINK1 promotes colorectal cancer progression by downregulating Metallothioneins expression
- (2015) R Tiwari et al. Oncogenesis
- ZDOCK server: interactive docking prediction of protein-protein complexes and symmetric multimers
- (2014) B. G. Pierce et al. BIOINFORMATICS
- ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
- (2014) Carlos L. Arteaga et al. CANCER CELL
- Significant Association of Oncogene YAP1 with Poor Prognosis and Cetuximab Resistance in Colorectal Cancer Patients
- (2014) K.-W. Lee et al. CLINICAL CANCER RESEARCH
- Influence of comorbidity, age and performance status on treatment efficacy and safety of cetuximab plus irinotecan in irinotecan-refractory elderly patients with metastatic colorectal cancer
- (2014) C.F. Jehn et al. EUROPEAN JOURNAL OF CANCER
- Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies
- (2014) Simonetta M. Leto et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Proteolytic Activation of the Porcine Epidemic Diarrhea Coronavirus Spike Fusion Protein by Trypsin in Cell Culture
- (2014) Oliver Wicht et al. JOURNAL OF VIROLOGY
- Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent Evolution
- (2014) S. Misale et al. Cancer Discovery
- KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy
- (2013) Emanuele Valtorta et al. INTERNATIONAL JOURNAL OF CANCER
- Concomitant Tumor Expression of EGFR and TATI/SPINK1 Associates with Better Prognosis in Colorectal Cancer
- (2013) Selja Koskensalo et al. PLoS One
- Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
- (2013) Alberto Bardelli et al. Cancer Discovery
- Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
- (2012) Sandra Misale et al. NATURE
- The road to resistance: EGFR mutation and cetuximab
- (2012) Alberto Bardelli et al. NATURE MEDICINE
- Therapeutic Targeting of SPINK1-Positive Prostate Cancer
- (2011) B. Ateeq et al. Science Translational Medicine
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search